When to Bridge and When NOT to Bridge Warfarin
Bridging warfarin with heparin should be AVOIDED in the vast majority of patients, including those with atrial fibrillation and most mechanical heart valves, as bridging increases major bleeding 2-3 fold without reducing thromboembolism risk. 1, 2
DO NOT BRIDGE (Most Patients)
The default approach is NO bridging for:
- Atrial fibrillation patients at low-to-moderate thrombotic risk (CHADS₂ score ≤3)
- Bileaflet mechanical aortic valves without additional risk factors
- Venous thromboembolism (VTE) patients >3 months from acute event
- Any patient undergoing minimal or low-bleeding-risk procedures
The evidence is clear: bridging therapy increases major bleeding by 2-3 fold (OR 4.44 in one study) without preventing stroke or thromboembolism 3, 4. The PERIOP-2 trial demonstrated similar thromboembolism rates across all patient populations regardless of bridging, but significantly increased bleeding with postoperative bridging 1.
CONSIDER BRIDGING (Very Limited Indications)
Bridge ONLY in very high thrombotic risk patients:
Mechanical Heart Valves - The Only Strong Indication
- Mechanical MITRAL valve (any type)
- Older generation mechanical aortic valve (ball-cage, tilting disc)
- Any mechanical valve PLUS:
- Prior stroke/TIA within 6 months
- CHADS₂ score ≥5
- Multiple mechanical valves
Other Potential High-Risk Scenarios (Weaker Evidence)
- Recent VTE (<3 months) with ongoing high risk
- Antiphospholipid syndrome with prior thrombotic events 5
- Recent arterial thromboembolism (<3 months)
Practical Bridging Protocol (When Indicated)
For the rare patient requiring bridging 2:
Pre-Procedure:
- Stop warfarin 5 days before procedure
- Start therapeutic-dose LMWH (enoxaparin 1 mg/kg BID or 1.5 mg/kg daily) on Day -3
- Give last LMWH dose on morning of Day -1 at half the total daily dose
- Target INR <1.5 on procedure day
Post-Procedure:
- Low/moderate bleeding risk: Resume warfarin evening of Day 0 or Day 1
- High bleeding risk: Resume warfarin Day 1-2
- Consider low-dose LMWH (enoxaparin 40 mg daily) for VTE prophylaxis first 24-72 hours
- Resume therapeutic LMWH 2-3 days post-procedure only if bridging was truly indicated
- Continue LMWH until INR therapeutic (≥2.0) for 24 hours
Critical Pitfalls to Avoid
The most common error is over-bridging. Studies show that 33-40% of bridged patients are actually low-to-moderate thrombotic risk and should NOT be bridged 5.
Key considerations:
- HAS-BLED score ≥1 significantly increases bleeding risk with bridging 3
- Bridging at warfarin initiation (not just interruption) also increases bleeding without benefit 3
- Older patients, especially women >60 years, have higher bleeding risk 6
- The bleeding risk from bridging often exceeds the thrombotic risk from brief warfarin interruption
Special Populations
For patients with bileaflet aortic valves: The 2024 AHA/ACC guidelines note that available data support limiting bridging use, with careful consideration of individual bleeding risk using HAS-BLED scores and personal bleeding history 1.
For VTE patients: Most bridging episodes occur >3 months from acute event, often justified by breakthrough VTE or concurrent APS 5. These populations warrant careful risk-benefit assessment, as standard VTE alone >3 months out does NOT require bridging.